Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing
Summary
Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing
Detailed description
This study supports the collection of tumor specimens for CLIA-certified genomic testing and research testing in parallel. CLIA-certified tests have established measurements of accuracy and precision which allow for return of results. This study does not involve treatment, only testing, which could be used to meet eligibility criteria in other trials or therapies. This study includes a registry for longitudinal evaluation of patients whose cancer has FGFR mutations such as cholangiocarcinoma, pancreatic cancer, and others (telehealth).
Arms & interventions
- OtherBiospecimen collection
Specimens to be collected include a fresh tumor biopsy, previously obtained tumor specimens or blocks (if available), whole blood, serum, plasma and buccal smear.
Outcome measures
Primary
Number of participants receiving new therapy based on study findings
Impact on clinical care
Time frame: Up to 24 Months
Secondary
Average number of days to return results
Time frame: Up to 24 months
Eligibility criteria
Study locations (1)
Ohio State University Wexner Medical Center
Columbus, Ohio, 43210
References
- Krook MA, Bonneville R, Chen HZ, Reeser JW, Wing MR, Martin DM, Smith AM, Dao T, Samorodnitsky E, Paruchuri A, Miya J, Baker KR, Yu L, Timmers C, Dittmar K, Freud AG, Allenby P, Roychowdhury S. Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy. Cold Spring Harb Mol Case Stud. 2019 Aug 1;5(4):a004002. doi: 10.1101/mcs.a004002. Print 2019 Aug.(PubMed)